San Diego, CA – March 1st, 2010 - Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-322, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. AVN-322 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-322 in Alzheimer’s disease later this year.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
